Evidence map›Paper›PMID 40263948›Full record

Trial reportCancer science2025

Pyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial.

Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing and 14 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Huan LiDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Min YanDepartment of Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Zhaohui LiDepartment of Oncology, Anshan Cancer Hospital, Anshan, China.
Xiujie CuiDepartment of Oncology, Chaoyang Central Hospital, Chaoyang, China.
Xuening JiDepartment of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Fengqi FangDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yuyang ZhangDepartment of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, China.
Yan WangDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Xiangyu GuoDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Mingxi JingDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Zhichao GaoDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Hui CaoDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Fangyuan DongDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Jie WuDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Cui JiangDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Yangyang DuanDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Xiaorui LiDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Yujun JiangDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Lei JiangDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Ying EDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Yufeng JiaDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Liang ZhangDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
Pai PengOncology Business Unit, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Tao SunDepartment of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.ORCID https://orcid.org/0000-0001-5931-386X

Funding

Chinese Society of Clinical Oncology Y-HR2018-362
6 · The paper itself

Abstract

Trastuzumab and pertuzumab combined with chemotherapy represent the standard therapy for first-line treatment of HER2-positive metastatic breast cancer (BC). Due to challenges related to availability and cost in China, it is necessary to explore treatments involving tyrosine kinase inhibitors (TKIs). In this multicenter, single-arm, open-label phase II trial, patients with HER2-positive BC were enrolled from seven hospitals in China. Patients received oral pyrotinib 400 mg once daily and intravenous nab-paclitaxel 125 mg/m

Indexed as

AcrylamidesAlbuminsAminopyridinesAminoquinolinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPaclitaxelAdultAgedFemaleHumansMiddle AgedProspective StudiesTreatment Outcome130-nm albumin-bound paclitaxelAcrylamidesAlbuminsAminopyridinesAminoquinolinesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelpyrotinibbreast cancerHER2nab‐paclitaxelpyrotinibtyrosine kinase inhibitor

Identifiers

PMID40263948
PMCPMC12210037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.